These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26925841)

  • 1. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
    Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
    BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
    Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K
    Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
    Hart LS; Rader J; Raman P; Batra V; Russell MR; Tsang M; Gagliardi M; Chen L; Martinez D; Li Y; Wood A; Kim S; Parasuraman S; Delach S; Cole KA; Krupa S; Boehm M; Peters M; Caponigro G; Maris JM
    Clin Cancer Res; 2017 Apr; 23(7):1785-1796. PubMed ID: 27729458
    [No Abstract]   [Full Text] [Related]  

  • 4. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
    Zhang L; Scorsone K; Woodfield SE; Zage PE
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
    Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
    Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
    Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
    J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
    Ahsan S; Ge Y; Tainsky MA
    Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
    Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
    Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
    See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
    Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
    Hölzel M; Huang S; Koster J; Ora I; Lakeman A; Caron H; Nijkamp W; Xie J; Callens T; Asgharzadeh S; Seeger RC; Messiaen L; Versteeg R; Bernards R
    Cell; 2010 Jul; 142(2):218-29. PubMed ID: 20655465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
    Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
    Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
    Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
    Maiti A; Naqvi K; Kadia TM; Borthakur G; Takahashi K; Bose P; Daver NG; Patel A; Alvarado Y; Ohanian M; DiNardo CD; Cortes JE; Jabbour EJ; Garcia-Manero G; Kantarjian HM; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):142-148.e1. PubMed ID: 30635233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
    Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
    Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.